GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY22 results · Apr–Jun 2021
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹789.99 crore (up 21.8% from Q1 FY21) and net profit of ₹121.08 crore (up 9.2% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 789.99 | 648.59 | +21.8% | 813.75 | −2.9% |
| Other income | 31.73 | 57.92 | −45.2% | 29.60 | +7.2% |
| Total income | 821.72 | 706.51 | +16.3% | 843.35 | −2.6% |
| Profit before tax | 164.90 | 149.14 | +10.6% | 63.01 | +161.7% |
| Net profit for the period | 121.08 | 110.83 | +9.2% | 14.33 | +744.9% |
| EPS, basic (₹) | 7.15 | 6.54 | +9.3% | 0.85 | +741.2% |
| Net margin (%) | 15.3 | 17.1 | 1.8 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 773.46 | 648.65 | +19.2% | 807.27 | −4.2% |
| Other income | 31.73 | 57.79 | −45.1% | 29.61 | +7.2% |
| Total income | 805.19 | 706.44 | +14.0% | 836.88 | −3.8% |
| Profit before tax | 163.92 | 149.29 | +9.8% | 60.92 | +169.1% |
| Net profit for the period | 120.40 | 110.96 | +8.5% | 12.74 | +845.1% |
| EPS, basic (₹) | 7.11 | 6.55 | +8.5% | 0.75 | +848.0% |
| Net margin (%) | 15.6 | 17.1 | 1.6 |
Consolidated
- Filed with BSE
- 27 Jul 2021, 08:40 IST
- Board meeting
- 26 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2021, 08:40 IST
- Board meeting
- 26 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE